San Diego-centered Viking Therapeutics marked itself as a serious competitor in the weight loss drug marketplace in February just after revealing promising information from a mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as in March the c

Wegovy would be the Variation of semaglutide which is intended additional for weight loss. Novo Nordisk described at the end of December that there was total availability of all doses of Wegovy for pharmacies nationwide. This was after months of "unprecented" need for Wegovy asto aid adults and children aged 12 many years and more mature with being